Genentech at neutral by Merrill

Genentech was given a neutral rating by Merrill Lynch analyst Eric Ende. The FDA granted priority review to Lucentis in wet age-related macular degeneration, with a late-June PDUFA date. Two-year data from Marina suggested sustained efficacy, as expected. Shares of the South San Francisco pharmaceutical company were down 74 cents, or 0.86%, at $84.95 on volume of 4,183,000 shares versus the three-month running average of 3,305,590 shares. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.